nascobal (r) (b 12) demand is strong







Re: zaks on par 2 minutes ago par trades slightly above book value most of which is cash and with a PE under 10

par is poorly covered by WS and is unknown like snts

par has a market cap of 800m and did over 1b in sales in 2009

par is on track for fda approval in april of a branded agent that will add over a buck or more in earnings and a second candidate later in 2010

zeg lawsuit is a blib to PRX but critically important to your beloved sn

2 points on that devastating upcoming event

since prx has yet to release the generic, snts is basically fighting to keep it off market with virtually no chance of any large financial gain, if any

and two prx bats 90% and the judge was highly critical of snts and urged sn to settle as your new ceo admits

in sum prx is a superior inv vs teva wpi bvf snts et al
 






congrats fda action today $140M 8 second(s) ago par has 180 day market exclusivity 140m annual sales just out


Drug Details


Drug Name(s) AMLODIPINE; VALSARTAN (Generic Drug)
FDA Application No. (ANDA) 090011
Active Ingredient(s) AMLODIPINE; VALSARTAN
Company PAR PHARM
Original Approval or Tentative Approval Date March 19, 2010

Sentiment : Strong Buy Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------
 




































fda approval in days 9 second(s) ago oravig on target expecting fda approval in days now

oravig expected to do $$100m annually ++ at peak

nascobal had its best week ever with total scripts over 1700 UP over 7% from prior week

unbelievable with pe under 10 par is poised for a breakout

stay tuned

Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------
 






breakout is long overdue


fda approval in days 9 second(s) ago oravig on target expecting fda approval in days now

oravig expected to do $$100m annually ++ at peak

nascobal had its best week ever with total scripts over 1700 UP over 7% from prior week

unbelievable with pe under 10 par is poised for a breakout

stay tuned

Sentiment : Strong Buy
Rating :
(No ratings) the_p_compa...

24/Male



--------------------------------------------------------------------------------
 












zaks gives prx the highest rating

.Par Pharmaceutical Companies Inc. (PRX): Zacks Rank Buy

Tracey Ryniec, On Friday April 9, 2010, 1:00 am EDT
Par Pharmaceutical Companies Inc. (NYSE: PRX - News) has surprised on the Zacks Consensus Estimate 4 quarters in a row by an average of 47%. PRX is trading with a forward P/E of only 12.6.

Company Description

Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States.

It has two divisions, Par Pharmaceutical, its generic drug segment, and Strativa Pharmaceuticals, its proprietary products segment which launched in 2005.

It currently markets and/or licenses more than 85 prescription drug products and has more than 30 products in active development.

Par Surprised in the Fourth Quarter by 14%

On Feb 24, Par Pharmaceutical reported fourth quarter results which beat the Zacks consensus by 8 cents. Earnings per share were 65 cents compared to the Zacks Consensus of 57 cents. This is also higher than the fourth quarter of 2008, where the company reported 21 cents.

Revenue rose 80% to $290.3 million from $161.3 million in the fourth quarter of 2008. For the full year, revenue jumped to $1.193 billion from $578 million in 2008.

The revenue gain was attributed to limited competition in metoprolol succinate, sumatriptan succinate, meclizine, and dronabinol.

Additionally, the launch of nateglinide and clonidine in the third quarter, and tramadol ER in the fourth quarter 2009, boosted quarterly revenue.

Tramadol ER was launched in Nov 2009 in 100mg and 200mg strengths. It is the generic version of Ortho-McNeil's Ultrama ER product of which annual U.S. sales are approximately $150 million.

Par has about 27 ANDAs pending with the FDA with 12 first-to-file opportunities with brand value of approximately $6.3 billion.

Zacks Consensus Estimates Climb

Analysts liked what they heard in February.

Estimates have been slowly rising. The first quarter Zacks Consensus is up 2 cents to 65 cents in the last 30 days.

The 2010 Zacks Consensus has increased by 4 cents to $2.01 per share. This is up sharply from just 90 days ago when analysts expected $1.64 per share.

The company reports first quarter results on May 1.

Value Fundamentals

Par Pharmaceutical is a Zacks #1 Rank (strong buy) stock. It has a price-to-book ratio of 1.8 which is under the industry average o 2.0 and within the value parameter of under 3.0.

The company also has a solid 1-year return on equity (ROE) of 18.9%.

Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor in charge of the market-beating Zacks Value Trader service.


PAR PHARMA COS (PRX): Free Stock Analysis Report
 






























other then 1 or 2 individuals who post here often, par has an outstanding sales force


congrats on sales success and we await similar success on upcoming launches for 2 new products